Normacor® was presented at the BIOTECHMED conference, which was held on September 14-15 in Gelendzhik with the participation of Veronika Skvortsova, Minister of Health of the Russian Federation, Denis Manturov, Minister of Industry and Trade of the Russian Federation, Sergey Chemezov, Head of the Russian Technologies State Corporation, and Veniamin Kondratiev, Governor of the region.
Normacor is the world's only cardioplegic drug developed for conducting normothermal open-heart surgery during bypass.
The drug was developed by Russian specialists and has passed all necessary efficacy and safety studies in accordance with the current legislation of the Russian Federation. The actual exclusion of ischemia and reperfusion injury provides a high degree of protection for the heart without limiting the duration of surgery.
Detailed information about the conference can be found in the press release on the website of ChemRar Group
Normacor is the world's only cardioplegic drug developed for conducting normothermal open-heart surgery during bypass.
The drug was developed by Russian specialists and has passed all necessary efficacy and safety studies in accordance with the current legislation of the Russian Federation. The actual exclusion of ischemia and reperfusion injury provides a high degree of protection for the heart without limiting the duration of surgery.
Detailed information about the conference can be found in the press release on the website of ChemRar Group
